OMER
Price
$4.39
Change
+$0.14 (+3.29%)
Updated
Nov 5, 04:00 PM (EDT)
One day until earnings call
RXRX
Price
$6.82
Change
+$0.18 (+2.71%)
Updated
Nov 5, 04:00 PM (EDT)
One day until earnings call
Ad is loading...

OMER vs RXRX

Header iconOMER vs RXRX Comparison
Open Charts OMER vs RXRXBanner chart's image
Omeros
Price$4.39
Change+$0.14 (+3.29%)
Volume$58.27K
CapitalizationN/A
Recursion Pharmaceuticals
Price$6.82
Change+$0.18 (+2.71%)
Volume$656.57K
CapitalizationN/A
View a ticker or compare two or three
OMER vs RXRX Comparison Chart
Loading...
OMER
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
OMER vs. RXRX commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OMER is a Hold and RXRX is a Hold.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (OMER: $4.25 vs. RXRX: $6.62)
Brand notoriety: OMER and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OMER: 116% vs. RXRX: 75%
Market capitalization -- OMER: $246.27M vs. RXRX: $1.93B
OMER [@Biotechnology] is valued at $246.27M. RXRX’s [@Biotechnology] market capitalization is $1.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OMER’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • OMER’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, OMER is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OMER’s TA Score shows that 6 TA indicator(s) are bullish while RXRX’s TA Score has 1 bullish TA indicator(s).

  • OMER’s TA Score: 6 bullish, 3 bearish.
  • RXRX’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, OMER is a better buy in the short-term than RXRX.

Price Growth

OMER (@Biotechnology) experienced а -0.23% price change this week, while RXRX (@Biotechnology) price change was -3.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +14.28%, and the average quarterly price growth was +9.90%.

Reported Earning Dates

OMER is expected to report earnings on Feb 26, 2025.

RXRX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.93B) has a higher market cap than OMER($246M). OMER YTD gains are higher at: 29.969 vs. RXRX (-32.860). OMER has higher annual earnings (EBITDA): -166.68M vs. RXRX (-348.35M). RXRX has more cash in the bank: 474M vs. OMER (159M). RXRX has less debt than OMER: RXRX (89.9M) vs OMER (213M). RXRX has higher revenues than OMER: RXRX (48.6M) vs OMER (0).
OMERRXRXOMER / RXRX
Capitalization246M1.93B13%
EBITDA-166.68M-348.35M48%
Gain YTD29.969-32.860-91%
P/E RatioN/AN/A-
Revenue048.6M-
Total Cash159M474M34%
Total Debt213M89.9M237%
FUNDAMENTALS RATINGS
OMER: Fundamental Ratings
OMER
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
11
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OMERRXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
OMER
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASVRX10.640.02
+0.19%
American Century Small Cap Value R
IIGZX11.800.01
+0.08%
Voya Global High Dividend Low Vol Port I
FMUFX14.710.01
+0.07%
Federated Hermes Muni and Stock Adv F
GMVRX16.51N/A
N/A
Goldman Sachs Small/Mid Cap Value R
APAYX11.14-0.02
-0.18%
Integrity Dividend Summit A

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with NTLA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
+4.17%
NTLA - OMER
43%
Loosely correlated
+2.30%
CRSP - OMER
42%
Loosely correlated
-0.28%
VCYT - OMER
40%
Loosely correlated
+2.07%
RXRX - OMER
40%
Loosely correlated
+3.44%
INZY - OMER
39%
Loosely correlated
+1.38%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+3.44%
BEAM - RXRX
63%
Loosely correlated
+6.24%
CRSP - RXRX
56%
Loosely correlated
-0.28%
PRME - RXRX
56%
Loosely correlated
-1.49%
EXAI - RXRX
55%
Loosely correlated
+2.24%
NTLA - RXRX
54%
Loosely correlated
+2.30%
More